These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 27875973)

  • 21. Discovery of novel DAPY-IAS hybrid derivatives as potential HIV-1 inhibitors using molecular hybridization based on crystallographic overlays.
    Huang B; Wang X; Liu X; Chen Z; Li W; Sun S; Liu H; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    Bioorg Med Chem; 2017 Aug; 25(16):4397-4406. PubMed ID: 28659246
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Revealing the drug-resistant mechanism for diarylpyrimidine analogue inhibitors of HIV-1 reverse transcriptase.
    Zhang H; Qin F; Ye W; Li Z; Ma S; Xia Y; Jiang Y; Zhu J; Li Y; Zhang J; Chen HF
    Chem Biol Drug Des; 2011 Sep; 78(3):427-37. PubMed ID: 21696545
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and anti-human immunodeficiency virus activity of substituted ( o,o-difluorophenyl)-linked-pyrimidines as potent non-nucleoside reverse transcriptase inhibitors.
    Čechová L; Dejmek M; Baszczyňski O; Šaman D; Gao L; Hu E; Stepan G; Jansa P; Janeba Z; Šimon P
    Antivir Chem Chemother; 2019; 27():2040206619826265. PubMed ID: 30788976
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Design, synthesis, and antiviral evaluation of novel piperidine-substituted arylpyrimidines as HIV-1 NNRTIs by exploring the hydrophobic channel of NNIBP.
    Zhang T; Zhou Z; Zalloum WA; Wang Z; Fu Z; Cherukupalli S; Feng D; Sun Y; Gao S; De Clercq E; Pannecouque C; Kang D; Zhan P; Liu X
    Bioorg Chem; 2021 Nov; 116():105353. PubMed ID: 34536931
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-Based Optimization of Thiophene[3,2-d]pyrimidine Derivatives as Potent HIV-1 Non-nucleoside Reverse Transcriptase Inhibitors with Improved Potency against Resistance-Associated Variants.
    Kang D; Fang Z; Huang B; Lu X; Zhang H; Xu H; Huo Z; Zhou Z; Yu Z; Meng Q; Wu G; Ding X; Tian Y; Daelemans D; De Clercq E; Pannecouque C; Zhan P; Liu X
    J Med Chem; 2017 May; 60(10):4424-4443. PubMed ID: 28481112
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 2: discovery of novel [1,2,4]Triazolo[1,5-a]pyrimidines using a structure-guided core-refining approach.
    Wang L; Tian Y; Chen W; Liu H; Zhan P; Li D; Liu H; De Clercq E; Pannecouque C; Liu X
    Eur J Med Chem; 2014 Oct; 85():293-303. PubMed ID: 25089812
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 1.
    Hopkins AL; Ren J; Milton J; Hazen RJ; Chan JH; Stuart DI; Stammers DK
    J Med Chem; 2004 Nov; 47(24):5912-22. PubMed ID: 15537346
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis of pyrimidine and quinolone conjugates as a scaffold for dual inhibitors of HIV reverse transcriptase and integrase.
    Wang Z; Vince R
    Bioorg Med Chem Lett; 2008 Feb; 18(4):1293-6. PubMed ID: 18226894
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Arylazolyl(azinyl)thioacetanilides. Part 16: Structure-based bioisosterism design, synthesis and biological evaluation of novel pyrimidinylthioacetanilides as potent HIV-1 inhibitors.
    Li X; Lu X; Chen W; Liu H; Zhan P; Pannecouque C; Balzarini J; De Clercq E; Liu X
    Bioorg Med Chem; 2014 Oct; 22(19):5290-7. PubMed ID: 25150090
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacophore-fusing design of pyrimidine sulfonylacetanilides as potent non-nucleoside inhibitors of HIV-1 reverse transcriptase.
    Sang Y; Pannecouque C; De Clercq E; Zhuang C; Chen F
    Bioorg Chem; 2020 Mar; 96():103595. PubMed ID: 32006797
    [TBL] [Abstract][Full Text] [Related]  

  • 31. 2-(2,6-Dihalophenyl)-3-(pyrimidin-2-yl)-1,3-thiazolidin-4-ones as non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Rao A; Balzarini J; Carbone A; Chimirri A; De Clercq E; Monforte AM; Monforte P; Pannecouque C; Zappalà M
    Antiviral Res; 2004 Aug; 63(2):79-84. PubMed ID: 15302136
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Discovery of novel indolylarylsulfones as potent HIV-1 NNRTIs via structure-guided scaffold morphing.
    Zhao T; Meng Q; Kang D; Ji J; De Clercq E; Pannecouque C; Liu X; Zhan P
    Eur J Med Chem; 2019 Nov; 182():111619. PubMed ID: 31434039
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Triazinone Derivative Inhibits HIV-1 Replication by Interfering with Reverse Transcriptase Activity.
    Urano E; Miyauchi K; Kojima Y; Hamatake M; Ablan SD; Fudo S; Freed EO; Hoshino T; Komano J
    ChemMedChem; 2016 Oct; 11(20):2320-2326. PubMed ID: 27634404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of Dihydrofuro[3,4- d]pyrimidine Derivatives as Novel HIV-1 Non-Nucleoside Reverse Transcriptase Inhibitors with Promising Antiviral Activities and Desirable Physicochemical Properties.
    Kang D; Zhang H; Wang Z; Zhao T; Ginex T; Luque FJ; Yang Y; Wu G; Feng D; Wei F; Zhang J; De Clercq E; Pannecouque C; Chen CH; Lee KH; Murugan NA; Steitz TA; Zhan P; Liu X
    J Med Chem; 2019 Feb; 62(3):1484-1501. PubMed ID: 30624934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evolution of anti-HIV drug candidates. Part 3: Diarylpyrimidine (DAPY) analogues.
    Ludovici DW; De Corte BL; Kukla MJ; Ye H; Ho CY; Lichtenstein MA; Kavash RW; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Heeres J; Koymans LM; de Jonge MR; Van Aken KJ; Daeyaert FF; Das K; Arnold E; Janssen PA
    Bioorg Med Chem Lett; 2001 Sep; 11(17):2235-9. PubMed ID: 11527705
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Discovery of piperidine-linked pyridine analogues as potent non-nucleoside HIV-1 reverse transcriptase inhibitors.
    Chen X; Li Y; Ding S; Balzarini J; Pannecouque C; De Clercq E; Liu H; Liu X
    ChemMedChem; 2013 Jul; 8(7):1117-26. PubMed ID: 23650275
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C Substitutions.
    Lai MT; Munshi V; Lu M; Feng M; Hrin-Solt R; McKenna PM; Hazuda DJ; Miller MD
    Viruses; 2016 Sep; 8(10):. PubMed ID: 27669286
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fragment hopping-based discovery of novel sulfinylacetamide-diarylpyrimidines (DAPYs) as HIV-1 nonnucleoside reverse transcriptase inhibitors.
    Han S; Sang Y; Wu Y; Tao Y; Pannecouque C; De Clercq E; Zhuang C; Chen FE
    Eur J Med Chem; 2020 Jan; 185():111874. PubMed ID: 31735575
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Design, synthesis and anti-HIV evaluation of novel diarylpyridine derivatives targeting the entrance channel of NNRTI binding pocket.
    Yang J; Chen W; Kang D; Lu X; Li X; Liu Z; Huang B; Daelemans D; Pannecouque C; De Clercq E; Zhan P; Liu X
    Eur J Med Chem; 2016 Feb; 109():294-304. PubMed ID: 26802545
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Design of non-nucleoside inhibitors of HIV-1 reverse transcriptase with improved drug resistance properties. 2.
    Freeman GA; Andrews Iii CW; Hopkins AL; Lowell GS; Schaller LT; Cowan JR; Gonzales SS; Koszalka GW; Hazen RJ; Boone LR; Ferris RG; Creech KL; Roberts GB; Short SA; Weaver K; Reynolds DJ; Milton J; Ren J; Stuart DI; Stammers DK; Chan JH
    J Med Chem; 2004 Nov; 47(24):5923-36. PubMed ID: 15537347
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.